Outcomes of Venous Thromboembolism in patients with Thrombocytopenia- A multi-center retrospective cohort study

Technical Summary: Outcomes of Venous Thromboembolism in Patients with Thrombocytopenia

Problem Statement
Acute venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of morbidity and mortality. While prompt anticoagulation (AC) is the standard of care and significantly improves survival in the general VTE population, its management is complicated in patients with thrombocytopenia (platelet count <150 k/uL). These patients face a therapeutic dilemma: they require anticoagulation to prevent fatal clot extension but possess an elevated risk of major hemorrhage. Furthermore, thrombocytopenia often coexists with conditions that independently increase VTE risk, such as malignancies. Despite the clinical prevalence of this scenario, robust longitudinal data regarding real-world treatment decisions and survival outcomes in this specific population are scarce.

Methodology
This study employed a multi-center, retrospective cohort design using the TriNetX Global Collaborative Network, which aggregates data from 171 healthcare organizations.

• Cohort Definition: The study identified 1,893,091 patients with acute VTE (defined by ICD-10 codes for PE or DVT). From this pool, a thrombocytopenic cohort (n=33,208) was defined by having a platelet count ≤149,000/µL on the day of VTE diagnosis, with at least two instances of low counts to mitigate spurious results. A control cohort (n=1,147,511) consisted of VTE patients with platelet counts ≥150,000/µL.
• Sub-group Stratification: The thrombocytopenic group was further stratified by severity: Mild (100–149 k/µL), Moderate (50–99 k/µL), Severe (20–49 k/µL), and Very Severe (<19 k/µL).
• Statistical Analysis: To minimize confounding, 1:1 propensity score matching (PSM) was performed based on demographics, comorbidities, VTE severity, and bleeding risk factors. Post-matching, the thrombocytopenic cohort included 32,158 patients. Outcomes were assessed at 7 days, 30 days, 90 days, and 1 year using Kaplan-Meier survival analysis and hazard ratios (HR).

Key Contributions and Results
The study provides real-world evidence on the management and outcomes of VTE in the context of varying degrees of thrombocytopenia.

• Mortality: Thrombocytopenic patients demonstrated significantly higher all-cause mortality compared to controls at all time points. The hazard ratios for mortality at 1 year ranged from 3.42 to 4.92. Sub-group analysis revealed a severity gradient; for instance, at 7 days, the HR for severe thrombocytopenia was 10.2 (95% CI 6.69–15.7) compared to controls, while even mild thrombocytopenia showed a significantly elevated HR of 3.6.
• Treatment Patterns:
  • Anticoagulation: Usage of full-dose anticoagulation was significantly lower in patients with severe and very severe thrombocytopenia. Conversely, patients with mild thrombocytopenia were more likely to receive anticoagulation than controls.
  • IVC Filters: Placement of inferior vena cava (IVC) filters within 7 days was significantly higher across mild, moderate, and severe thrombocytopenia subgroups (Relative Risks ranging from 4.55 to 6.77) compared to controls.
• Recurrence and Bleeding:
  • Recurrent VTE: Despite higher IVC filter usage, thrombocytopenic patients experienced higher rates of recurrent PE and DVT up to 1 year. For example, recurrent DVT risk was elevated across all severity levels, with very severe thrombocytopenia showing a relative risk (RR) of 1.84 at 1 year.
  • Bleeding: Major bleeding events, including intracranial hemorrhage (ICH), were significantly more frequent in thrombocytopenic patients. Notably, even mild thrombocytopenia was associated with a four-fold increased risk of ICH compared to controls.
• Transfusion: Outcomes regarding blood and platelet transfusions could not be reliably assessed due to low event counts relative to the sample size.

Significance and Claims
The authors claim that this study highlights a distinct, high-risk population where the presence of thrombocytopenia at the time of VTE diagnosis portends persistently worse survival and higher risks of both bleeding and thrombotic recurrence for at least one year.

Key conclusions drawn by the paper include:

1. Broad Risk: The adverse impact of thrombocytopenia is not limited to severe cases; even mild thrombocytopenia is associated with significantly higher mortality and bleeding risks.
2. Therapeutic Trade-offs: The data illustrates the clinical trade-off where severe thrombocytopenia leads to the withholding of life-saving anticoagulation and increased reliance on IVC filters. However, the study notes that increased filter use did not prevent higher rates of recurrent VTE, suggesting that filters alone may not mitigate the pro-thrombotic milieu in these patients.
3. Clinical Implication: The findings underscore the need for tailored management strategies that balance bleeding and thrombosis risks, potentially requiring a multi-disciplinary approach.
4. Limitations: The authors modestly acknowledge that as an observational study, unmeasured confounders (such as the severity of underlying malignancy or organ failure) may influence outcomes. Additionally, the reliance on coding data introduces potential misclassification bias, and VTE-specific mortality could not be isolated from all-cause mortality.

The paper concludes that while current guidelines offer some direction, further prospective studies are necessary to refine treatment approaches for this high-risk population.